Cargando…

Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date

Previous reports have described the appearance of systemic lupus erythematosus (SLE) cases following interferon-α (IFN-α) therapy, IFN-regulated gene expression is significantly increased in SLE, and an association between SLE and gene variants belonging to IFN downstream pathways has been shown. Ba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Felten, Renaud, Scher, Florence, Sagez, Flora, Chasset, François, Arnaud, Laurent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514126/ https://www.ncbi.nlm.nih.gov/pubmed/31190735 http://dx.doi.org/10.2147/DDDT.S170969

Ejemplares similares

Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge
por: Dima, Alina, et al.
Publicado: (2022)

Anifrolumab for systemic lupus erythematosus
Publicado: (2022)

Anifrolumab for Adolescent Discoid Lupus Erythematosus
por: Shaw, Katharina S., et al.
Publicado: (2023)

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
por: Furie, Richard, et al.
Publicado: (2017)

Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus
por: Chia, Yen Lin, et al.
Publicado: (2022)

Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date
por: Lenert, Aleksander, et al.
Publicado: (2017)

Anifrolumab for Moderate and Severe Muco-Cutaneous Lupus Erythematosus: A Monocentric Experience and Review of the Current Literature
por: Paolino, Giovanni, et al.
Publicado: (2023)

Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus
por: Chia, Yen Lin, et al.
Publicado: (2021)

Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment
por: Kirou, Kyriakos A., et al.
Publicado: (2022)

Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus
por: Almquist, Joachim, et al.
Publicado: (2022)

Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review
por: Liu, Zhihui, et al.
Publicado: (2022)

Alopecia secondary to severe discoid lupus responding to anifrolumab
por: Han, Shannon, et al.
Publicado: (2023)

OA14 The role of anifrolumab in treating life threatening systemic lupus erythematosus with severe mucocutaneous involvement
por: Baldwin, Christopher, et al.
Publicado: (2023)

Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international survey
por: Petitdemange, Arthur, et al.
Publicado: (2021)

Role of Anifrolumab in Refractory Cutaneous Manifestations of Lupus Erythematosus: A Case Series and Literature Review
por: Khan, Muhammad Atif, et al.
Publicado: (2023)

Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice
por: Tanaka, Yoshiya
Publicado: (2023)

Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
por: Morand, Eric F, et al.
Publicado: (2023)

Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
por: Bruce, Ian N, et al.
Publicado: (2022)

Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
por: Ballew, Nick, et al.
Publicado: (2022)

Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
por: Neupane, Binod, et al.
Publicado: (2023)

Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval
por: Loncharich, Michael F., et al.
Publicado: (2022)

Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus
por: Riggs, Jeffrey M, et al.
Publicado: (2018)

10 most important contemporary challenges in the management of SLE
por: Felten, Renaud, et al.
Publicado: (2019)

Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study
por: Felten, Renaud, et al.
Publicado: (2021)

Successful treatment of severe chronic cutaneous lupus with anifrolumab: A series of 6 cases
por: Kowalski, Eric H., et al.
Publicado: (2023)

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
por: Weisel, Katja
Publicado: (2016)

Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date
por: Lazzerini, Pietro Enea, et al.
Publicado: (2016)

Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date
por: Crotti, Chiara, et al.
Publicado: (2017)

Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
por: Galluzzo, M, et al.
Publicado: (2019)

Long‐Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open‐Label Extension Study
por: Chatham, W. Winn, et al.
Publicado: (2021)

A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus
por: Kalunian, Kenneth C., et al.
Publicado: (2022)

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date
por: Akamine, Takaki, et al.
Publicado: (2018)

Spotlight on fevipiprant and its potential in the treatment of asthma: evidence to date
por: Kao, Christina C, et al.
Publicado: (2019)

Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
por: Jia, Xiaoming, et al.
Publicado: (2020)

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus
por: Merrill, Joan T, et al.
Publicado: (2018)

Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab
por: Morand, Eric F, et al.
Publicado: (2018)

Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
por: Vachhani, Pankit, et al.
Publicado: (2016)

Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
por: Pellesi, Lanfranco, et al.
Publicado: (2017)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado, Álvaro, et al.
Publicado: (2018)

Long-term anifrolumab safe in SLE
por: McHugh, Jessica
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q89tbjsco63m5rpleoqvomm0k5